News
Roche returns rights to Taspoglutide to Ipsen
Roche has returned world rights (except Japan which are held by Teijin) to tasopglutide, the GLP-1 analogue for treatment of Type 2 Diabetes.
The rights are returned to Ipsen as the drug has experienced serious hypersensitivity problems (skin reactions and gastrointestinal symptoms).
Condition: Diabetes Type 2
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins